Skip to main content
D

DaShenLin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 603233 LEI · 300300TO4U1GUOTTHK82 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,436 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603233

About DaShenLin Pharmaceutical Group Co., Ltd.

DaShenLin Pharmaceutical Group Co., Ltd. is a large-scale enterprise specializing in the retail and distribution of pharmaceutical and health-related products. The company operates an extensive network of pharmacies, providing a wide range of products including prescription medications, over-the-counter drugs, traditional Chinese medicine, medical devices, and nutritional supplements. Beyond retail operations, the group is involved in pharmaceutical manufacturing, wholesale distribution, and logistics management. It emphasizes professional pharmaceutical services, offering health consultations and chronic disease management to its customers. By leveraging an integrated supply chain and digital health platforms, the company provides comprehensive healthcare solutions and improves accessibility to medical supplies.

Recent filings

Filing Released Lang Actions
大参林医药集团股份有限公司关于2026年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 1% confidence The document is a Shanghai Stock Exchange styled “公告” outlining a board‐approved “2026年度‘提质增效重回报’专项行动方案” (quality/efficiency improvement and shareholder return action plan). It is not a financial report (10-K, IR), not a dividend notice alone (DIV), not a proxy statement (PSI), nor a management change (MANG) or financing update (CAP). It presents operational strategy, governance enhancements, and investor return measures in a general announcement. As it does not fit any specific form category, it falls under the miscellaneous “Regulatory Filings” category (RNS).
2026-04-23 Chinese
大参林医药集团股份有限公司关于子公司申请银行综合授信额度及提供担保的公告
Capital/Financing Update Classification · 1% confidence The document is an official corporate announcement detailing the company’s subsidiaries applying for a combined bank credit facility and the parent company’s provision of guarantees up to CNY 8.82 billion. It outlines financing arrangements rather than reporting audited results, dividends, or share transactions. This is a financing update regarding debt facilities and guarantees, matching the Capital/Financing Update category (CAP).
2026-04-23 Chinese
大参林医药集团股份有限公司关于对子公司提供担保的进展公告
Regulatory Filings
2026-04-09 Chinese
大参林医药集团股份有限公司可转债转股结果暨股份变动公告
Regulatory Filings
2026-04-02 Chinese
总经理工作细则（2026年3月修订）
Regulatory Filings
2026-03-31 Chinese
大参林医药集团股份有限公司第五届董事会第一次会议决议公告
Regulatory Filings
2026-03-31 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.